Janssen Seeks FDA Approval of Teclistamab for RRMM

Janssen Seeks FDA Approval of Teclistamab for RRMM

315859

Janssen Seeks FDA Approval of Teclistamab for RRMM

Janssen is seeking the approval of its investigational therapy teclistamab in the U.S. for people with relapsed or refractory multiple myeloma (RRMM). “Despite all the gains that have been made in treating multiple myeloma, the unmet need still remains very high,” Peter Lebowitz, MD, PhD, global therapeutic area head of oncology at Janssen research and development, said in a press release. “Our relentless pursuit of treatments for this disease continues with the same sense of…

You must be logged in to read/download the full post.